Osimertinib (AZD9291)

For research use only. Not for use in humans.

目录号：S7297

Osimertinib (AZD9291) Chemical Structure

CAS No. 1421373-65-0

Osimertinib (AZD9291) 是口服不可逆的，突变选择性EGFR抑制剂，在 LoVo细胞中对Exon 19 缺失的 EGFR，L858R/T790M EGFR，和 WT EGFR的IC50分别为12.92，11.44 和 493.8 nM。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1203.93	现货
5mg	RMB 807.34	现货
10mg	RMB 1105.43	现货
100mg	RMB 5733.0	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Osimertinib (AZD9291)发表文献213篇：

Cell, 2020, 182(5):1232-1251.e22

PubMed: 32822576 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Nat Med, 2019, 25(1):111-118

PubMed: 30478424 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Nat Med, 2018, 24(5):638-646

PubMed: 29686424 ( click the link to review the publication )

Cancer Discov, 2015, 5(11):1155-63

PubMed: 26286086 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cell Rep, 2021, 34(3):108647

PubMed: 33472066 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):17

PubMed: 33461557 ( click the link to review the publication )

EBioMedicine, 2021, 64:103220

PubMed: 33529999 ( click the link to review the publication )

Acta Pharmacol Sin, 2021, 10.1038/s41401-020-00577-1

PubMed: 33414509 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4607

PubMed: 32929081 ( click the link to review the publication )

Sci Immunol, 2020, 31;5(43) pii: eaav3937

PubMed: 32005679 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Clin Cancer Res, 2020, 20 pii: clincanres

PubMed: 32312893 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2321

PubMed: 31953310 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Theranostics, 2020, 15;10(14):6122-6135

PubMed: 32483443 ( click the link to review the publication )

Cancer Res, 2020, 80(21):4655-4667

PubMed: 32873635 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Cancer Lett, 2020, 28;483:46-58

PubMed: 32272148 ( click the link to review the publication )

Cancers (Basel), 2020, 13(1)E111

PubMed: 33396393 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32183160 ( click the link to review the publication )
Cell Death Dis, 2020, 14;11(4):230

PubMed: 32286266 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):214

PubMed: 33033232 ( click the link to review the publication )

Cancer Discov, 2020, 15 pii: CD-20-0116

PubMed: 32414908 ( click the link to review the publication )

Hum Mol Genet, 2020, ddaa268

PubMed: 33326033 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3813-3823

PubMed: 32735723 ( click the link to review the publication )

Lung Cancer, 2020, 5;145:48-57

PubMed: 32408132 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-20-0664

PubMed: 33106373 ( click the link to review the publication )

Front Oncol, 2020, 9:1503

PubMed: 31993373 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.16135

PubMed: 33247550 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )

Ann Transl Med, 2020, 8(6):366

PubMed: 32355810 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002/tox.22899

PubMed: 31916386 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 534:1-7

PubMed: 33302159 ( click the link to review the publication )

J Oncol, 2020, 17;2020:6249829

PubMed: 32256584 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

J Med Invest, 2020, 67(3.4):343-350

PubMed: 33148913 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):169

PubMed: 33287873 ( click the link to review the publication )

Cancer Sci, 2020, 111(7):2374-2384

PubMed: 32391602 ( click the link to review the publication )

Nat Cancer, 2020, 1(3):359-369

PubMed: 33345196 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:652

PubMed: 32793596 ( click the link to review the publication )

Pharmaceutics, 2020, 12(10)E939

PubMed: 33008019 ( click the link to review the publication )

Cells, 2020, 9(12)E2596

PubMed: 33287368 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-0443-1

PubMed: 32704041 ( click the link to review the publication )
Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Physiol Rep, 2020, 8(13):e14490

PubMed: 32652816 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-0457-8

PubMed: 32678313 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11236

PubMed: 32641854 ( click the link to review the publication )

Food Funct, 2020, 11(3):2714-2724

PubMed: 32163057 ( click the link to review the publication )

Viruses, 2020, 12(11)E1294

PubMed: 33198108 ( click the link to review the publication )

Rapid Commun Mass Spectrom, 2020, 10.1002/rcm.8955

PubMed: 32990383 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(4):656-671

PubMed: 30578931 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3329-3340

PubMed: 30770351 ( click the link to review the publication )

Neuro Oncol, 2019, 10.1093/neuonc/noz206

PubMed: 31678994 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Cell Syst, 2019, 10.1016/j.cels.2019.10.002

PubMed: 31668800 ( click the link to review the publication )

Biomaterials, 2019, 219:119400

PubMed: 31398570 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2808

PubMed: 31806641 ( click the link to review the publication )

Int J Cancer, 2019, 145(5):1432-1444

PubMed: 30784054 ( click the link to review the publication )

Oncogene, 2019, 38(5):656-670

PubMed: 30171258 ( click the link to review the publication )

Oncogene, 2019, 38(37):6399-6413

PubMed: 31324888 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers, 2019, 11(3)

PubMed: 30818860 ( click the link to review the publication )

Signal Transduct Target Ther, 2019,

PubMed: 32651361 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(6):1193-1203

PubMed: 31867165 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):112-126

PubMed: 30322949 ( click the link to review the publication )
Mol Cancer Ther, 2019, 18(9):1593-1601

PubMed: 31253648 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(8):1708-1721

PubMed: 31497352 ( click the link to review the publication )

Lung Cancer, 2019, 127:146-152

PubMed: 30642543 ( click the link to review the publication )

Lung Cancer, 2019, 137:85-93

PubMed: 31563735 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(11):7427-7437

PubMed: 31454149 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(12):2607-2614

PubMed: 31754333 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:3419-3432

PubMed: 31114376 ( click the link to review the publication )

Ann Transl Med, 2019, 7(22):651

PubMed: 31930052 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 379:114662

PubMed: 31301315 ( click the link to review the publication )

J Cell Biochem, 2019, 120(1):756-767

PubMed: 30145802 ( click the link to review the publication )

Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1059-1066

PubMed: 30483795 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3129748

PubMed: 31346515 ( click the link to review the publication )

Thorac Cancer, 2019, 10(10):1868-1878

PubMed: 31486270 ( click the link to review the publication )

Breast Cancer (Dove Med Press), 2019, 11:231-241

PubMed: 31839713 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):955-961

PubMed: 31289574 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(10):1689-1704

PubMed: 31314158 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 7(1):161-184

PubMed: 30522949 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )
Oncotarget, 2019, 10(26):2546-2560

PubMed: 31069016 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5692

PubMed: 30952931 ( click the link to review the publication )

Transl Lung Cancer Res, 2019, 8(4):340-351

PubMed: 31555510 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2019, 22(5):264-270

PubMed: 31109435 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4655

PubMed: 30405134 ( click the link to review the publication )

J Thorac Oncol, 2018, 13(7):915-925

PubMed: 29702287 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3097-3107

PubMed: 29506987 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(22):5610-5621

PubMed: 29967248 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cancer Res, 2018, 10.1158/0008-5472.CAN-18-0505

PubMed: 30026325 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):109

PubMed: 30157900 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800011R

PubMed: 29812969 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):740-750

PubMed: 29467275 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2257-2265

PubMed: 30049789 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(1):99-109

PubMed: 29269566 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

Nanomedicine (Lond), 2018, 13(10):1107-1120

PubMed: 29874151 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Front Cell Neurosci, 2018, 12:21

PubMed: 29456493 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):19

PubMed: 29764505 ( click the link to review the publication )
Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(3):239-247

PubMed: 29333953 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2018, 10.1007/s00432-018-2668-7

PubMed: 29797219 ( click the link to review the publication )

Cancer Med, 2018, 7(1):208-218

PubMed: 29239135 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):1046-1054

PubMed: 29917169 ( click the link to review the publication )

Environ Toxicol, 2018, 33(11):1153-1159

PubMed: 30136359 ( click the link to review the publication )

Radiat Res, 2018, 189(3):283-291

PubMed: 29332537 ( click the link to review the publication )

Pharmazie, 2018, 73(11):630-634

PubMed: 30396380 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

JCI Insight, 2018, 3(24)

PubMed: 30568033 ( click the link to review the publication )

JCI Insight, 2018, 3(11)

PubMed: 29875309 ( click the link to review the publication )

Oncotarget, 2018, 9(101):37520-37533

PubMed: 30680067 ( click the link to review the publication )

Oncotarget, 2018, 9(76):34240-34258

PubMed: 30344940 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

Nanomedicine (Lond), 2018, 13(10):1107-1120

PubMed: 29874151 ( click the link to review the publication )

Sci Transl Med, 2017, 9(415)

PubMed: 29118262 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

J Natl Cancer Inst, 2017, 1;109(9):djx014

PubMed: 28376152 ( click the link to review the publication )

J Thorac Oncol, 2017, 12(5):884-889

PubMed: 28088511 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Genes Dev, 2017, 31(2):184-196

PubMed: 28167502 ( click the link to review the publication )
Neuro Oncol, 2017, 19(12):1628-1639

PubMed: 28575494 ( click the link to review the publication )

Cancer Res, 2017, 77(11):2990-3000

PubMed: 28416483 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3527-3539

PubMed: 28522751 ( click the link to review the publication )

Cancer Res, 2017, 10.1158/0008-5472

PubMed: 28202511 ( click the link to review the publication )

Cancer Res, 2017, 77(5):1200-1211

PubMed: 28082405 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.21536

PubMed: 28199182 ( click the link to review the publication )

J Med Chem, 2017, 60(17):7447-7458

PubMed: 28787156 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28830985 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):357-364

PubMed: 27913578 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(3):506-515

PubMed: 28138027 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 27913578 ( click the link to review the publication )

Mol Oncol, 2017,

PubMed: 28388009 ( click the link to review the publication )

J Mol Biol, 2017, 429(14):2211-2230

PubMed: 28539250 ( click the link to review the publication )

Eur J Med Chem, 2017, 140:510-527

PubMed: 28987609 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(7):915-928

PubMed: 28289161 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(11):1542-1550

PubMed: 28784613 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(7):852-861

PubMed: 28314843 ( click the link to review the publication )

Mol Pharm, 2017, 14(7):2368-2377

PubMed: 28597653 ( click the link to review the publication )

Lung Cancer, 2017, 108:96-102

PubMed: 28625657 ( click the link to review the publication )
Lung Cancer, 2017, 109:1-8

PubMed: 28577937 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )

Clin Lung Cancer, 2017, 18(3):281-285

PubMed: 28038979 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 321:18-26

PubMed: 28237877 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5281-5288

PubMed: 29138581 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

J Vis Exp, 2017, (126)

PubMed: 28829429 ( click the link to review the publication )

Oncotarget, 2017, 8(62):105479-105491

PubMed: 29285266 ( click the link to review the publication )

Oncotarget, 2017, 8(41):70736-70751

PubMed: 29050315 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 8(22):36331-36338

PubMed: 28422737 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109319-109331

PubMed: 29312610 ( click the link to review the publication )

Oncotarget, 2017, 8(62):104894-104912

PubMed: 29285221 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15441

PubMed: 29133857 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29050315 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )

Oncotarget, 2017, 8(22):36331-36338

PubMed: 28422737 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Mol Cell, 2016, 63(3):526-38

PubMed: 27453044 ( click the link to review the publication )

Nat Commun, 2016, 7:11815

PubMed: 27283993 ( click the link to review the publication )
Cancer Immunol Res, 2016, 4(11):936-947

PubMed: 27680026 ( click the link to review the publication )

Oncogene, 2016, 10.1038/onc.2016.216

PubMed: 27345413 ( click the link to review the publication )

J Med Chem, 2016, 59(13):6187-200

PubMed: 27266526 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(12):3040-3054

PubMed: 27612490 ( click the link to review the publication )

Cancer Sci, 2016, 107(8):1134-40

PubMed: 27240419 ( click the link to review the publication )

Mol Pharm, 2016, 13(6):2117-25

PubMed: 27169328 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84951-84964

PubMed: 27825114 ( click the link to review the publication )

Oncotarget, 2016, 7(30):47998-48010

PubMed: 27384992 ( click the link to review the publication )

Oncotarget, 2016, 7(17):23608-32

PubMed: 27015562 ( click the link to review the publication )

Sci Rep, 2016, 6:37997

PubMed: 27897231 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(23):5305-13

PubMed: 26206867 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Sci Signal, 2015, 8(379):ra53

PubMed: 26038598 ( click the link to review the publication )

J Med Chem, 2015, 58(16):6589-606

PubMed: 26258521 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143333

PubMed: 26580964 ( click the link to review the publication )

J Natl Compr Canc Netw, 2013, 11(10):1249-61

PubMed: 24142826 ( click the link to review the publication )

Methods Mol Biol, 2011, 685:91-109

PubMed: 20981520 ( click the link to review the publication )

Expert Opin Pharmacother, 2010, 11(8):1263-76

PubMed: 20429667 ( click the link to review the publication )

产品安全说明书

EGFR抑制剂选择性比较

生物活性

产品描述

特性

Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.

靶点

L858R/T790M EGFR ^[1] (LoVo cells)	Exon 19 deletion EGFR ^[1] (LoVo cells)	WT EGFR ^[1] (LoVo cells)
11.44 nM	12.92 nM	493.8 nM

体外研究

与体外野生型相比，在突变EGFR 细胞系中AZD9291能更有效的抑制增殖。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PC-9/BRc1	MX3GeY5kfGmxbjDBd5NigQ>?	MV[1NEBvVQ>?	MV6yOEBp	MXTEUXNQ	MnTzbY5lfWOnczDlfJBz\XO\|aX;uJI9nKHSqZTDwdo9ieG:ydH;0bYMhSkOOLUKg[oFucWy7IH3lcYJmeiCESV2=	NEHV[GE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O\|MzPSd-MkW0O\|c{OjV:L3G+
PC-9/ERc1	M3PTSmZ2dmO2aX;uJGF{e2G7	M2n1blUxKG6P	MUSyOEBp	M2\oeGROW09?	NYrDb45LcW6mdXPld{BmgHC{ZYPzbY9vKG:oIITo[UBxem:jcH;weI91cWNiQlPMMVIh\mGvaXz5JI1mdWKncjDCTW0>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
VP-2	Ml;4SpVv[3Srb36gRZN{[Xl?	MWm1NEBvVQ>?	M4W4XlI1KGh?	MlriSG1UVw>?	M2TZVIlv\HWlZYOg[ZhxemW\|c3nvckBw\iC2aHWgdJJw[XCxcITveIlkKEKFTD2yJIZidWmueTDt[Y1j\XJiQlnN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
PC-9/BRc1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn:zOVAhdk1?	MnTVNVAh\A>?	M1K4Z2ROW09?	MlznbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDsc45oNXSncn2gLFExNWSjeTmg[5Jwf3SqIHnubIljcXSrb36gZZN{[Xm\|	MnvmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N\|I2RC:jPh?=
PC-9/ERc1	NHXPNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWe1NEBvVQ>?	NHf6VGIyOCCm	NUiwdYxrTE2VTx?=	MofDbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDsc45oNXSncn2gLFExNWSjeTmg[5Jwf3SqIHnubIljcXSrb36gZZN{[Xm\|	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
VP-2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX61NEBvVQ>?	NIOzNIEyOCCm	MWDEUXNQ	MWLpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHzvcocufGW{bTCoNVAu\GG7KTDndo94fGhiaX7obYJqfGmxbjDhd5NigXN?	M2PZbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe3N\|I2Lz5{NUS3O\|MzPTxxYU6=
PC9 GR4	M{LOT2Z2dmO2aX;uJGF{e2G7	NGmwXXoxNTFyIN88US=>	MojkO\|IhcA>?		NVW2RYhtcW6qaXLpeJPDqEWJRmKgdIhwe3Cqb4L5cIF1cW:wIHHu[EBld3ewc4Ty[YFuKHOrZ37hcIlv\8Li	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2OE[zN{c,OjV7NEi2N\|M9N2F-
PC9	MYXGeY5kfGmxbjDBd5NigQ>?	MnvaNE0yOCEQvF2=	NGXKcIY4OiCq		MVPpcohq[mm2czDXWEBGT0[UIHH0JIxwfyClb37j[Y51emG2aX;udy=>	MnruQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NEi2N\|MoRjJ3OUS4OlM{RC:jPh?=
PC9 GR4	MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LrelAuOTBizszN	M4nYUVczKGh?		NVHmd4tZcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>?	MmPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NEi2N\|MoRjJ3OUS4OlM{RC:jPh?=
BAF3	NWTofYFITnWwY4Tpc44h[XO\|YYm=		NWrZN2pZPzJiaB?=		MUPHTVUxKD1iMD6wNFA{KM7:TR?=	NVj5SHNURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3	M1rsT2Z2dmO2aX;uJIF{e2G7		MXm3NkBp		NHXYTm9IUTVyIE2gNE4xODB\|IN88US=>	NGrGVFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BAF3	NYPnb5JbTnWwY4Tpc44h[XO\|YYm=		M2P6c\|czKGh?		NV\YTpJ2T0l3MDC9JFAvODBzIN88US=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827	M{TuPWZ2dmO2aX;uJIF{e2G7		NXXlVJh{PzJiaB?=		M1;aOmdKPTBiPTCwMlAxOSEQvF2=	MlX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
PC9	MlPFSpVv[3Srb36gZZN{[Xl?		MY[3NkBp		MkDWS2k2OCB;IECuNFAzKM7:TR?=	NXmweHpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3	NVvn[FNsTnWwY4Tpc44h[XO\|YYm=		NX3oW4pUPCCq		NGTQXm5GSzVyIE2gNE4xODJizszN	MnvNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
HCC827	MVPGeY5kfGmxbjDhd5NigQ>?		M1nmVFMhcA>?		NYfSe\|BQUUN3MDC9JFAvODB{NTFOwG0>	MoLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2M{O4NlkoRjJ5NEOzPFI6RC:jPh?=
H1975	NXiwZZExTnWwY4Tpc44h[XO\|YYm=		NGrhPZo{KGh?		NFvYUoFKSzVyIE2gNE4xODJ3IN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR\|M{iyPUc,Ojd2M{O4Nlk9N2F-
H3255	NFW0TI9HfW6ldHnvckBie3OjeR?=		NUHremQyOyCq		MX;JR\|UxKD1iMD6wNFQyKM7:TR?=	M4XuZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEOzPFI6Lz5{N{SzN\|gzQTxxYU6=
NCI-H1975	NHPUN2dHfW6ldHnvckBie3OjeR?=		M3vQOlczKGh?		Mlz3S2k2OCB;IECuNFA2KM7:TR?=	MmH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
PC9	NG\2N5hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MXi3NkBp		NH31e2lKSzVyIE2gNE4xODZ3IN88US=>	NGj6Vnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEexOlY1OSd-Mki3NVY3PDF:L3G+
NCI-H1975	MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NFTRSIw4OiCq		M2XTdmlEPTBiPTCwMlAyODVizszN	NYO5fWVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVY3PDFpPkK4O\|E3PjRzPD;hQi=>
Sf21	MnT3SpVv[3Srb36gZZN{[Xl?				MkL3TWM2OCB;IECuNFEzKM7:TR?=	M2Dqe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm2NlY4Lz5{N{m5OlI3PzxxYU6=
PC9-DRH	NWThXJlpTnWwY4Tpc44h[XO\|YYm=		Ml7tNkBp		NGPYZXhKSzVyIE2gNE4xOTNizszN	MkDZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
BAF3	NWTEPHljTnWwY4Tpc44h[XO\|YYm=		NXHqWYxHPzJiaB?=		MkTUS2k2OCB;IECuNFE{KM7:TR?=	Mon0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
HCC827	MkPkSpVv[3Srb36gZZN{[Xl?		M{nYfFk3KGh?		Mn23SWM2OCB;IECuNFE1KM7:TR?=	MlPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MkWyOlkoRjJ6MkK1NlY6RC:jPh?=
HCC827	NXLxfIxOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MXq5OkBp		MUDFR\|UxKD1iMD6wNVQh\|ryP	M{X0e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N\|U4PTxxYU6=
NCI-H1975	NGPSSVVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MYC5OkBp		M3zzTGVEPTBiPTCwMlAyPCEQvF2=	M1\5VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N\|U4PTxxYU6=
NCI-H1975	NXvPNmVFTnWwY4Tpc44h[XO\|YYm=		NHvvOIEzKGh?		M33IcmlEPTBiPTCwMlAyPSEQvF2=	Ml\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
H1975	MU\GeY5kfGmxbjDhd5NigQ>?		MXeyJIg>		NULrRpNDUUN3MDC9JFAvODF3IN88US=>	M3zEeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OU[4NlU{Lz5{Nkm2PFI2OzxxYU6=
PC9	MXHGeY5kfGmxbjDhd5NigQ>?		NEfJfIIzKGh?		MVnJR\|UxKD1iMD6wNVch\|ryP	MlfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NkiyOVMoRjJ4OU[4NlU{RC:jPh?=
NCI-H1975	MmnSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M4TxWFczKGh?		MXLJR\|UxKD1iMD6wNVkh\|ryP	NXrMdlg3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OlY4PzNpPkK5OFY3Pzd\|PD;hQi=>
NCI-H1975	NYHVdll3TnWwY4Tpc44h[XO\|YYm=		NWHvSWt4QTZiaB?=		M3rqbGVEPTBiPTCwMlAyQSEQvF2=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ{NUK2PUc,Ojh{MkWyOlk9N2F-
NCI-H1975	NVnzR414SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NUfFU2YzQTZiaB?=		MnHZSWM2OCB;IECuNFE6KM7:TR?=	Mlj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4MEO5PVEoRjJ6NkCzPVkyRC:jPh?=
NCI-H1975	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MmC3O\|IhcA>?		NHjkbIxKSzVyIE2gNE4xOTlizszN	NIjsOWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi1N\|M1OCd-Mkm4OVM{PDB:L3G+
HCC827	MWrGeY5kfGmxbjDhd5NigQ>?		M3XHZ\|IhcA>?		NHT1elZKSzVyIE2gNE4xOjNizszN	NIG0[Gk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
NCI-H1975	MljQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MlvPO\|IhcA>?		NU\vcWd[UUN3MDC9JFAvODJ\|IN88US=>	NFnqbos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFkzPid-Mkm1N\|Q6OjZ:L3G+
PC9	MWDDfZRwfG:6aXPpeJkh[XO\|YYm=		MXy3NkBp		MWLHTVUxKD1iMD6wNlMh\|ryP	MlfPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
NCI-H1975	NHHZWohEgXSxdH;4bYNqfHliYYPzZZk>		MU[3NkBp		M2qwUGdKPTBiPTCwMlAzPCEQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
HCC827	MknNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MXq3NkBp		Ml3UTWM2OCB;IECuNFI2PCEQvF2=	M3rv[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUe2NlczLz5{OUW3OlI4OjxxYU6=
HCC827	M2GwUGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M4i1UFczKGh?		MXrJR\|UxKD1iMD6wNlch\|ryP	MnfUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O\|MoRjJ7NE[2O\|c{RC:jPh?=
HCC827	NE[xPXVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MmmyO\|IhcA>?		M2i1emlEPTBiPTCwMlAzPyEQvF2=	MnHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUOzOFAoRjJ7OEWzN\|QxRC:jPh?=
NCI-H1975	NY\mNpE3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M3XKPFczKGh?		MkLFTWM2OCB;IECuNFMh\|ryP	M2q2fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEOzOVc6Lz5{OECzN\|U4QTxxYU6=
H3255	MoLKSpVv[3Srb36gZZN{[Xl?		MW[3NkBp		Mme3S2k2OCB;IECuNFM{KM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H3255	NFL1Um5HfW6ldHnvckBie3OjeR?=		MUiyJIg>		NH3qW2hKSzVyIE2gNE4xOzZizszN	NHzHRm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
NCI-H1975	NETK[XJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NGPSS4w4OiCq		M{DOS2lEPTBiPTCwMlA1OSEQvF2=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd\|MEG5Nkc,Ojl5M{CxPVI9N2F-
NCI-H1975	M37sdmZ2dmO2aX;uJIF{e2G7		NWj6VGZKOSCq		MlfETWM2OCB;IECuNFQyKM7:TR?=	Mmi0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{S5NlYoRjJ7NUO0PVI3RC:jPh?=
BAF3	NVfsN\|hlTnWwY4Tpc44h[XO\|YYm=		MUe0JIg>		MonsSWM2OCB;IECuNFQ{KM7:TR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975	MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MmfqO\|IhcA>?		M1TGOmlEPTBiPTCwMlA1PzJizszN	NF7HOlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW3OlI4Oid-Mkm1O\|YzPzJ:L3G+
NCI-H1975	Mlv6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NFHibng4OiCq		M1z1dWlEPTBiPTCwMlA2OiEQvF2=	M{HoWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxOlM6Lz5{N{GzNVY{QTxxYU6=
PC9	MorGSpVv[3Srb36gZZN{[Xl?		NWPlb3VQOiCq		M3LaZWlEPTBiPTCwMlA2PiEQvF2=	MoO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
NCI-H1975	NF7sc\|dEgXSxdH;4bYNqfHliYYPzZZk>		MkfGO\|IhcA>?		Mnf5TWM2OCB;IECuNFYh\|ryP	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR6Nkm1N{c,Ojl2OE[5OVM9N2F-
HCC827	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?				MnrGTWM2OCB;IECuNFYyPiEQvF2=	NYLHOWh3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6QTZpPkK4OFI3QTl4PD;hQi=>
NCI-H1975	NHu3OVlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=				M{C1bGlEPTBiPTCwMlA3PyEQvF2=	M3LtXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
HaCaT	NGTZXJJHfW6ldHnvckBie3OjeR?=		MWGzJIg>		NUGwPYxYUUN3MDC9JFAvODd\|NzFOwG0>	NFzPNIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN\|gzQSd-Mke0N\|M5Ojl:L3G+
NCI-H1975	MnHhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NFLjdGo4OiCq		NETzNHBKSzVyIE2gNE4yOyEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
A431	NIPKd4RHfW6ldHnvckBie3OjeR?=		MoXZNUBp		NYqxb4VnUUN3MDC9JFAvOTRzIN88US=>	NF:3TlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFkzPid-Mkm1N\|Q6OjZ:L3G+
A549	MWTGeY5kfGmxbjDhd5NigQ>?				NGHINndKSzVyIE2gNE4yPSEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
Calu3	NVnsc4JjS3m2b4TvfIlkcXS7IHHzd4F6		MXq3NkBp		MlLDS2k2OCB;IECuNlY1KM7:TR?=	MlzSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
Sf9	MnvPSpVv[3Srb36gZZN{[Xl?		M{K4SlIxKG2rboO=		M3HPSGlEPTBiPTCwMlI4QCEQvF2=	NV\peGxCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0PFIyPTFpPkK4OFgzOTVzPD;hQi=>
BAF3	MkHQSpVv[3Srb36gZZN{[Xl?		M1rwTlczKGh?		MWXHTVUxKD1iMD6zJO69VQ>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3	MmXySpVv[3Srb36gZZN{[Xl?		NEezUHU4OiCq		NYPyUWVET0l3MDC9JFAvOzFizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H460	MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NIPv[G84OiCq		MV;JR\|UxKD1iMD60NVU6KM7:TR?=	MmHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5MU[2OFEoRjJ6N{G2OlQyRC:jPh?=
LoVo	MY\GeY5kfGmxbjDhd5NigQ>?		NHHLepIzKGh?		Mm\NTWM2OCB;IECuOFgh\|ryP	NYGxPGw3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OlgzPTNpPkK2PVY5OjV\|PD;hQi=>
LoVo	NHXCc49HfW6ldHnvckBie3OjeR?=		M4fiTVIhcA>?		NEPBOnVKSzVyIE2gNE41QCEQvF2=	M1fWXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm2NlY4Lz5{N{m5OlI3PzxxYU6=
A549	MonIRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NWewWW1ZPzJiaB?=		NUG4fGx2UUN3MDC9JFAvPDh4IN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV5NkK3Nkc,Ojl3N{[yO\|I9N2F-
BAF3	NIrRbZhHfW6ldHnvckBie3OjeR?=		Mln6O\|IhcA>?		MWLHTVUxKD1iMD61JO69VQ>?	M{DsNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
A549	M3P0WGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NVPtVmZYPzJiaB?=		M2G5VmlEPTBiPTCwMlU{KM7:TR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O\|M9N2F-
A549	NIG0T2FEgXSxdH;4bYNqfHliYYPzZZk>		NXHwTWdRPzJiaB?=		NUHBVYdXUUN3MDC9JFAvPTNizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh3M{O0NEc,Ojl6NUOzOFA9N2F-
BAF3	NH7Id5ZHfW6ldHnvckBie3OjeR?=		Ml\SO\|IhcA>?		NHHsPFlIUTVyIE2gNE42PSEQvF2=	M37HNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
BAF3	MXjGeY5kfGmxbjDhd5NigQ>?		MVG3NkBp		M1T4VmdKPTBiPTCwMlU3KM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HEK293	MYfGeY5kfGmxbjDhd5NigQ>?				NVKyeHdzUUN3MDC9JFAvPTdizszN	NIi2eG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
BAF3	NWmycHZ7TnWwY4Tpc44h[XO\|YYm=		MkDWO\|IhcA>?		M1fyTWdKPTBiPTCwMlU6KM7:TR?=	NH;3[VQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
A431	M1vqZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7				MmPVTWM2OCB;IECuOlE2PiEQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{Nkm5Okc,Ojh2Mk[5PVY9N2F-
HT-29	MkjxR5l1d3SxeHnjbZR6KGG\|c3H5		MonJO\|IhcA>?		NIHuSmxKSzVyIE2gNE43PSEQvF2=	NGToZpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS4Olk2Oyd-Mkm0PFY6PTN:L3G+
A431	NVTPU5RYTnWwY4Tpc44h[XO\|YYm=		MlP2PVYhcA>?		M2izPGVEPTBiPTCwMlY3PyEQvF2=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ{NUK2PUc,Ojh{MkWyOlk9N2F-
A431	MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		M2PyUVk3KGh?		MoS2SWM2OCB;IECuOlch\|ryP	M{nVWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N\|U4PTxxYU6=
A431	M3ny[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M3;ObFczKGh?		M3LFS2lEPTBiPTCwMlY5PSEQvF2=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV\|NEmyOkc,Ojl3M{S5NlY9N2F-
A431	NH6zOHZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MorxPVYhcA>?		NVOwc3FSTUN3MDC9JFAvPyEQvF2=	NXu4S5h{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2NFM6QTFpPkK4OlA{QTlzPD;hQi=>
A549	NV\ENYMyS3m2b4TvfIlkcXS7IHHzd4F6		M1T4R\|czKGh?		NEPQZmpKSzVyIE2gNE45PyEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR6Nkm1N{c,Ojl2OE[5OVM9N2F-
A431	MnLtRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MXy3NkBp		M2S5Z2lEPTBiPTCwMlg6OyEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|MU[zPUc,OjdzM{G2N\|k9N2F-
BA/F3	NEXsTHRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MVK3NkBp		NV22fIRbUUN3MDC9JFEh\|ryP	NY\iZlI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVg2OjFpPkK2NlU5PTJzPD;hQi=>
BAF3	NYLRboZHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXnMdYtSPzJiaB?=		MVLHTVUxKD1iMT6yJO69VQ>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H2122	M3T0dmZ2dmO2aX;uJIF{e2G7		NUjUXos2PzJiaB?=		MYrHTVUxKD1iMT6yJO69VQ>?	NUPIZVB[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
A431	NIfaNG1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NWn0Z2NEPzJiaB?=		NG\Kd2tKSzVyIE2gNU4zPCEQvF2=	MoDLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2Mkm5OVYoRjNyNEK5PVU3RC:jPh?=
A431	NHLMOVVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M3fJNVczKGh?		M{nHV2lEPTBiPTCxMlI3KM7:TR?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd\|MEG5Nkc,Ojl5M{CxPVI9N2F-
A431	M{\x[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NEPZOWE4OiCq		NInkcXVKSzVyIE2gNU43ODRizszN	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB\|M{W3PUc,OjhyM{O1O\|k9N2F-
A549	M{L5XGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M3jjWlk3KGh?		NHXyWmVGSzVyIE2gNU45OyEQvF2=	MoDmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
CHL	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3nVVVczKGh?		NYPCVFBFT0l3MDC9JFIvQSEQvF2=	NYLUV3hxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
H1355	NILnZpRHfW6ldHnvckBie3OjeR?=		MY[3NkBp		NIfqV49IUTVyIE2gN{DPxE1?	M1q2dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
H1703	NHHET3lHfW6ldHnvckBie3OjeR?=		NHLPNFk4OiCq		MlfLS2k2OCB;IEOuOUDPxE1?	Mme0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
A549	M2\KSmZ2dmO2aX;uJIF{e2G7		MWG3NkBp		MkL0S2k2OCB;IEOuOUDPxE1?	NXLOdYw2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
CHO	NUixdmw1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXSzO4lmPzJiaB?=		NXv5TI9WT0l3MDC9JFQvOiEQvF2=	MkTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
BAF3	M{jvfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MYG3NkBp		Mk\1TWM2OCB;IESuOlEh\|ryP	Mm\uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2Mkm5OVYoRjNyNEK5PVU3RC:jPh?=
BAF3	MnrJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NWjGUlNnPzJiaB?=		MX7JR\|UxKD1iNT6xOUDPxE1?	Ml;GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2Mkm5OVYoRjNyNEK5PVU3RC:jPh?=
BEAS2B	NIjTeIJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NYG5UIZjPzJiaB?=		MV\JR\|UxKD1iMUSuPUDPxE1?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
NCI-H1975	NHnjRY1HfW6ldHnvckBie3OjeR?=		NYHKOWhFOiCq		NY\RN4NNUUN3MDC9JFE2KM7:TR?=	MmX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
PC9	NUHkPGhsTnWwY4Tpc44h[XO\|YYm=		NEXtW4MzKGh?		NHyySmxKSzVyIE2gNVch\|ryP	NUXXSlF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
LoVo	MV3GeY5kfGmxbjDhd5NigQ>?		MVyyJIg>		MX;JR\|UxKD1iNEiwJO69VQ>?	NI\TO\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
NCI-H1975	MXvBcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl?				MXvBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEm3NG0h\G:3YnzlJI12fGGwdDD4[Y5w\3KjZoTl[EBqdiCVQ1nEJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFIvPSCvZz;r[{9l[XluIIDvJJFlKG[xcjC3JIRigXNicnXsZZRqfmVidH:gZ49vfHKxbB?=	MofNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
rat hepatocytes	NEnKNJpHfW6ldHnvckBie3OjeR?=				NFzSRXZKdnS{aX7zbYMh[2ynYYLhcoNmKGmwIILheEBp\XCjdH;jfZRmeyCvZXHzeZJm\CCyZYKgNVAoPiClZXzsdy=>	NXiw[HRwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
human hepatocytes	NVPwZVU{TnWwY4Tpc44h[XO\|YYm=				MkT6TY51emmwc3njJINt\WG{YX7j[UBqdiCqdX3hckBp\XCjdH;jfZRmeyCvZXHzeZJm\CCyZYKgNVAoPiClZXzsdy=>	NVfDeplrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
NCI-H1975	MYrBcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl?				MnXjRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGijcnLvdolv\yCHR1\SJGw5PTiUL2S5O\|BOKGSxdXLs[UBufXSjboSgfIVvd2e{YX\0[YQhcW5iU1PJSEBud3W\|ZTDhd5Nme3OnZDDhd{B1fW2xcjDndo94fGhiaX7obYJqfGmxbjDheEA2KG2pL3vnM4RigSxicH:gdYQh\m:{IEeg[IF6eyC{ZXzheIl3\SC2bzDjc451em:u	NXy0T4NIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
NCI-H1975	MlnUSpVv[3Srb36gZZN{[Xl?				NFHzRnZU\WynY4Tpeol1gSCrbnTlfEwhemG2aX:gc4YhUUN3MDDmc5IhTUeIUjDUO\|kxVS:OOEW4VkBld3WkbHWgcZV1[W62IHX4dJJme3OrbnegbJVu[W5iTlPJMWgyQTd3IHPlcIx{KHSxIFnDOVAh\m:{IIfpcIQhfHmyZTDFS2ZTKGW6cILld5NqdmdiaIXtZY4hSTR\|MTDj[Yxtew>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd\|MEG5Nkc,Ojl5M{CxPVI9N2F-
NCI-H1975	Mk\HRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				Mn7SRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgSWdHWiCWN{mwUU9NQDV6UjDkc5VjdGVibYX0ZY51KGW6cILld5NqdmdiaIXtZY4hVkOLLVixPVc2KGOnbHzzJJhmdm:pcnHmeIVlKGmwIFLBUGIw[yCjdHj5cYlkKG63ZHWgcY92e2ViYYPz[ZN{\WRiYYOgeJVud3JiZ4Lve5RpKGmwaHnibZRqd25iYYSgNVAhdWdxa3esJJBwKGKrZDDmc5IhOjFiZHH5dy=>	M1TNPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{OwNVkzLz5{OUezNFE6OjxxYU6=
HCC827	M3XVWGFxd3C2b4Ppd{Bie3OjeR?=				M4rne2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIFW3OFYuSTd3MDDk[YxmfGmxbjDteZRidnRiYYPz[ZN{\WRiYYOg[YFzdHliYYDvdJRwfGmlIHPlcIx{KGG2IEOgeW0h[W[2ZYKgNlQhcHK\|IHL5JGFvdmW6aX6gWk1HUVSFL4Dyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2comgLHJ3[iB;IEGuN\|QmMQ>?	NWf3S2ZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OlY4PzNpPkK5OFY3Pzd\|PD;hQi=>
HCC827	NH[xOFFCeG:ydH;zbZMh[XO\|YYm=				NYGyUHBEUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIR2M5OjdiY3XscJMhcGG{Yn;ybY5oKEWJRmKgSVc1Pi2DN{WwJIRmdGW2aX;uJI12fGGwdDDhd5Nme3OnZDDhd{Bt[XSnIHHwc5B1d3SrYzDj[YxteyCjdDCzJJVOKGGodHXyJFI1KGi{czDifUBCdm6neHnuJHYuTkmWQz;wdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlKG[ub4egZ5l1d22ndIL5JEhTfmJiPTCyO{4yPCVr	M4PTTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[2O\|c{Lz5{OUS2Olc4OzxxYU6=
A549	NEH0UWFHfW6ldHnvckBie3OjeR?=				NUHuTGVTW2WuZXP0bZZqfHlicnH0bY8hd2ZiSVO1NEBnd3JiaIXtZY4hSTV2OTDj[YxteyCneIDy[ZN{cW6pIIfpcIQufHmyZTDFS2ZTN0tvUnHzJI12fGGwdDD0c{BKSzVyIH\vdkBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQ>	NXWybmtJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PFY6PTNpPkK5OFg3QTV\|PD;hQi=>
HCC827	MlWwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		Mm\rO\|IhcA>?		NUfxZ5l[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR2M5OjdiY3XscJMh[XRiMTD1UUBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5JJJmdGG2aY\lJJRwKGOxboTyc4w>	NWXiUldoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1O\|YzPzJpPkK5OVc3Ojd{PD;hQi=>
BAF3	MUfGeY5kfGmxbjDhd5NigQ>?		NVO1NYZMOiCq		M1;HWGlvcGmkaYTpc44hd2ZiRVfGVkBVPzlyTT;MPFU5Wi:FN{m3V{BufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hdW:3c3WgRmFHOyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSWdHNWmwZIXj[YQhemWlZYD0c5IheGixc4Doc5J6dGG2aX;uJIF1KDFidH:gN{B2VSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KEWJRjDzeIlufWyjdHnvckBnd3JiMUWgcYlveyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	M3TTbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5\|MESyPVk2PjxxYU6=
BAF3	MX7GeY5kfGmxbjDhd5NigQ>?		NELmUXAzKGh?		NHTTW\|NKdmirYnn0bY9vKG:oIFXHSnIhOTmGL2S3PVBON0N5OUfTJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCRWY{KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDFS2YucW6mdXPl[EBz\WOncITvdkBxcG:\|cHjvdplt[XSrb36gZZQhOSC2bzCzJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhTUeIIIP0bY12dGG2aX;uJIZweiBzNTDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	M3PzXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5\|MESyPVk2PjxxYU6=
NCI-H1975	Mn;vRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				MVPBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFE6PzViY3XscJMhgGWwb3fyZYZ1\WRiaX6gV3RQS0tvRn;4clFvfS:QaoWgcpVl\SCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IHfyc5d1cCCjdDCyNEBu\y:tZz;kZZktKHCxIIHkJIZweiBzNDDkZZl{KHKnbHH0bZZmKHSxIIXueJJm[XSnZDDjc451em:u	M1:1eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{m1NlE6Lz5{OEO5OVIyQTxxYU6=
Caco2	NY\0W4JvTnWwY4Tpc44h[XO\|YYm=		M{LuSlIhcA>?		M2nrPWVn\my3eDDyZZRqdyCxZjDhdJBiemWwdDDw[ZJu\WGkaXzpeJkh\nKxbTDiZZNwdGG2ZYLhcEB{cWSnIITvJIFxcWOjbDDzbYRmKG:4ZYKgZZBq[2GuIIPp[IUhfG9iYnHzc4xifGW{YXygd4ll\SCxdnXyJIlvKGi3bXHuJGNi[29{IHPlcIx{KGG2IEWgeW0hcW6ldXLheIVlKG[xcjCyJIhzew>?	NIe2fnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
A431	MoTBSpVv[3Srb36gZZN{[Xl?				M3:4cnNmdGWldHn2bZR6KHKjdHnvJI9nKEWFNUCg[o9zKGi3bXHuJGE1OzFiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViRVfGVkB1dyCHQ{WwJIZweiCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgbIFz[m:{aX7nJGVITlJvTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfA>?	NIr5U3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
Caco2	NF7EVI9HfW6ldHnvckBie3OjeR?=		MlnZNkBp		NFrkcZdCeHCjcnXueEBx\XKvZXHibYxqfHliYXPyc5N{KGGyaXPhcEB1dyCkYYPvcIF1\XKjbDDzbYRmKGmwIHj1cYFvKEOjY3:yJINmdGy\|IHH0JFUhfU1iaX7jeYJifGWmIH\vdkAzKGi{cx?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
Caco2	NXHSZZZ4TnWwY4Tpc44h[XO\|YYm=		NYH4THlZOiCq		MVvBdJBiemWwdDDw[ZJu\WGkaXzpeJkh[WO{b4PzJIJie2:uYYTldoFtKHSxIHHwbYNidCC\|aXTlJIlvKGi3bXHuJGNi[29{IHPlcIx{KGG2IEWgeW0hcW6ldXLheIVlKG[xcjCyJIhzew>?	NXfCPVFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
NCI-H1975	MV\GeY5kfGmxbjDhd5NigQ>?		M2rrPFQhcA>?		M{PJfGlvcGmkaYTpc44hd2ZiRVfGVkBNQDV6Uj;UO\|kxVSCvdYThcpQhcW5iaIXtZY4hVkOLLVixPVc2KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFSqckOwPE9U\XJ2N{Ogd4l1\SCjdDCxJJVOKG2nYYP1doVlKGGodHXyJFQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	NFjXOoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827	MkK5SpVv[3Srb36gZZN{[Xl?		NXj2fVhpPCCq		MULJcohq[mm2aX;uJI9nKEWJRmKg[ZhwdiBzOTDk[YxmfGmxbjDteZRidnRiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFSqckOwPE9U\XJ2N{Ogd4l1\SCjdDCxJJVOKG2nYYP1doVlKGGodHXyJFQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	NIHDdIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
NCI-H1975	MYXBdI9xfG:\|aYOgZZN{[Xl?		MYC0PEBp		MnXTTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEe5NG0hdXW2YX70JIF{e2W\|c3XkJIF{KGOjc4Dhd4U{KGOuZXH2ZYdmKGG2IEGgeW0h[W[2ZYKgOFghcHK\|IHL5JIludXWwb3Lsc5R1cW6p	M1HOZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HCC827	NV35V2pkSXCxcITvd4l{KGG\|c3H5		MojNOFghcA>?		MVjJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFQ{iyO{Bk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyClYYPwZZNmNTNiY3zlZZZi\2ViYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhcW2vdX7vZoxwfHSrbne=	M3vKelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
PC9	M3jWb2Fxd3C2b4Ppd{Bie3OjeR?=		MXO0PEBp		MlPjTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCSQ{mgZ4VtdHNiaHHyZo9zcW6pIFXHSnIh\XixbjCxPUBl\WyndHnvckBufXSjboSgZZN{\XO\|ZXSgZZMh[2G\|cHHz[U0{KGOuZXH2ZYdmKGG2IEGgeW0h[W[2ZYKgOFghcHK\|IHL5JIludXWwb3Lsc5R1cW6p	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H3255	Mly1RZBweHSxc3nzJIF{e2G7		MWe0PEBp		MYPJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEh\|MkW1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSJI12fGGwdDDhd5Nme3OnZDDhd{Bk[XOyYYPlMVMh[2ynYY\h[4Uh[XRiMTD1UUBi\nSncjC0PEBpenNiYomgbY1ufW6xYnzveJRqdmd?	NXXNbWh7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H1975	M{HmemFxd3C2b4Ppd{Bie3OjeR?=		Mn3COFghcA>?		MlnRTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEe5NG0hdXW2YX70JIF{e2W\|c3XkJIF{KFCDUmCgZ4xm[X[jZ3WgZZQhOSC3TTDh[pRmeiB2ODDodpMh[nliaX3teY5w[myxdITpcoc>	Ml7PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
PC9	MkTsRZBweHSxc3nzJIF{e2G7		MljzOFghcA>?		NELDWJVKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIGDDPUBk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o	NHzTVnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827	NWi2TnJbSXCxcITvd4l{KGG\|c3H5		MoWyOFghcA>?		MXfJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFQ{iyO{Bk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H3255	NUTXPWZtSXCxcITvd4l{KGG\|c3H5		NXzDVml[PDhiaB?=		NVfieXBuUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIN\|I2PSClZXzsd{Bp[XKkb4LpcochTUeIUjDMPFU5WiCvdYThcpQh[XO\|ZYPz[YQh[XNiUFHSVEBkdGWjdnHn[UBifCBzIIXNJIFnfGW{IES4JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>?	NVnsdlFFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H1975	M2Li[WZ2dmO2aX;uJIF{e2G7				M{GyWHNmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KHSxIFnDOVAh\m:{IHj1cYFvKEF2M{GgZ4VtdHNiaHHyZo9zcW6pIIfpcIQufHmyZTDFS2ZT	MnvKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
human hepatocytes	MmH2SpVv[3Srb36gZZN{[Xl?				NVm5UZNqUW62cnnud4lkKGOuZXHyZY5k\SCrbjDoeY1idiCqZYDheI9kgXSnczDhd5Nme3OnZDDw[ZIhdWmubHnvckBk\Wyucx?=	Mmi3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
rat hepatocytes	NFewUlZHfW6ldHnvckBie3OjeR?=				M4H2cWlvfHKrboPpZ{BkdGWjcnHuZ4UhcW5icnH0JIhmeGG2b3P5eIV{KGG\|c3Xzd4VlKHCncjDtbYxtcW:wIHPlcIx{	NH7EdnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
A549, NCI-H1975	NYfpOGRuTnWwY4Tpc44h[XO\|YYm=				NFWyVpJU\WynY4Tpeol1gSC{YYTpc{Bw\iCLQ{WwJIZweiCHR1[td5RqdXWuYYTl[EB4cWymIIT5dIUhTUeIUjDpckBpfW2jbjDBOVQ6KGOnbHzzJJRwKEmFNUCg[o9zKEWJRmKgUFg2QFJxVEe5NG0h\G:3YnzlJI12fGGwdDDpckBpfW2jbjDOR2kuUDF7N{WgZ4VtdHN?	NGftb5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
A549, PC9	NYrUTGR2TnWwY4Tpc44h[XO\|YYm=				NHrHUolU\WynY4Tpeol1gSC{YYTpc{Bw\iCLQ{WwJIZweiCHR1[td5RqdXWuYYTl[EB4cWymIIT5dIUhTUeIUjDpckBpfW2jbjDBOVQ6KGOnbHzzJJRwKEmFNUCg[o9zKEWJRmKg[IVt\XSrb36gcZV1[W62IHnuJIh2dWGwIGDDPUBk\Wyucx?=	NWn6VnBMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
HCC827	NHrPenlCeG:ydH;zbZMh[XO\|YYm=				NU\BW3RbUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIR2M5OjdiY3XscJMhcGG{Yn;ybY5oKEWJRmKgSVc1PiC2bzDBO\|UxKGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyCnYYLsfUBieG:ydH;0bYMh[2WubIOgZZQhOyC3TTDh[pRmeiB{NDDodpMh[nliQX7u[ZhqdiCYLV\JWGMweHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDmcI94KGO7dH;t[ZRzgSBqUo\iJF0hOS5\|NDD0c{AyNjZ5JTm=	NYLibZN{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4OVM{PDBpPkK5PFU{OzRyPD;hQi=>
NCI-H1975	M1rTZWZ2dmO2aX;uJIF{e2G7				NFn3fYRKdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBxcG:\|cHjvdplt[XSrb36gbY4hTUeILYP0bY12dGG2ZXSgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGG2IEGgeI8hOTByIH7NJIJ6KFenc4Tldo4h[myxdDDt[ZRpd2R?	M3q3[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OUC2NVE1Lz5{OUmwOlEyPDxxYU6=
A431	NHf5OZBHfW6ldHnvckBie3OjeR?=				NIfkVXZU\WynY4Tpeol1gSC{YYTpc{whemG2aX:gTWM2OCCob4KgbJVu[W5iQUSzNUBk\WyuczDveoVz\XiycnXzd4lv\yC5aXzkMZR6eGViRVfGVkB1dyCLQ{WwJIZweiCqdX3hckBPS0lvSEG5O\|Uh[2WubIOg[ZhxemW\|c3nu[{BGT0[UIGS3PVBON0x6NUjSJI12fGGwdB?=	NXPwZms4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN\|E3OzlpPkK3NVMyPjN7PD;hQi=>
PC9	Ml7NRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				NUSzeHJ3SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gVGM6KGOnbHzzJIhiemKxcnnu[{BGT0[UIHX4c44hOTliZHXs[ZRqd25iYXP0bZZifGmwZzDteZRidnRieHXuc4dz[W[2ZXSgbY4hW0OLRDDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiCpcn;3eIghcW6qaXLpeIlwdiCjdDCxNEBu\y:tZz;kZZktKHCxIIHkJIZweiB5IHThfZMhemWuYYTpeoUhfG9iY3;ueJJwdA>?	M{LNPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
A431	MYDBcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl?				MmrYRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUSzNUBk\WyuczD4[Y5w\3KjZoTl[EBqdiCVQ1nEJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFUhdWdxa3ev[IF6NCCybzDx[EBnd3JiNzDkZZl{KHKnbHH0bZZmKHSxIHPvcpRzd2x?	NGrPR2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / p-AKT / p-ERK; PubMed: 28416483 Cancer Res PC-9/BRc1 cells were treated with the indicated doses of osimertinib. Drugs were refreshed every 24 hours. Cellular lysates were probed with the indicated antibodies. Osim: osimertinib. ABCB1; PubMed: 27649127 Molecules The effect of osimertinib at 0.3 μM on the expression of ABCB1 was measured in KB-3-1 and KB-C2 cell lines for 0, 24, 48, and 72 h.	28416483 27649127
Growth inhibition assay	Cell viability; PubMed: 31043587 Cell Death Dis Cells were treated with gefitinib or osimertinib for 72 h. Cell viability was measured by MTT assay. P < 0.05, P < 0.01, **P < 0.005 by t-test.	31043587
Immunofluorescence	Ki67 / γH2AX / p16; PubMed: 29212784 EMBO Mol Med PC9ER cells were treated for 5 days with either 3×mAbs (20 μg/ml), saline (CTRL), or with a low dose of osimertinib (2.5 nM). Shown are representative images of cells fixed in paraformaldehyde and immunostained for KI67 (panel E), γH2AX (panel F), and p16 (panel G). DAPI counterstaining was used to follow nuclear localization. Scale bar, 20 μm. The box and whisker plots, where the ends of the box are the upper and lower quartiles, depict quantifications of results obtained in three independent experiments. P ≤ 0.01, *P ≤ 0.001, n = 4; one-way ANOVA with Tukey's test.	29212784

体内研究

AZD9291（5mg / kg p.o.）引起整个EGFRm+（PC9）和EGFRm+/ T790M（H1975）肿瘤模型肿瘤中显著的肿瘤消退，伴随着对体内EGFR磷酸化和下游关键信号通路，如AKT和ERK的显著抑制。^[2]

动物实验： ^[2]	- 合并 Animal Models: PC9和H1975移植瘤小鼠 Dosages: ~5 毫克/千克 Administration: p.o. (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	99 mg/mL warmed (198.15 mM)
	Ethanol	43 mg/mL warmed (86.06 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+40%PEG300+5%Tween80+50%ddH2O	7.5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Osimertinib (AZD9291) SDF

分子量	499.61
化学式	C₂₈ H₃₃ N₇ O₂
CAS号	1421373-65-0
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02841579	Completed	Drug: Osimertinib	Non-Small Cell Lung Cancer	MedSIR\|AstraZeneca	August 2016	Phase 2
NCT02771314	Active not recruiting	Drug: AZD9291	Non Small Cell Lung Cancer	Hellenic Oncology Research Group	August 2 2016	Phase 2
NCT02511106	Active not recruiting	Drug: AZD9291 80 mg/40 mg\|Drug: Placebo AZD9291 80 mg/40 mg	Stage IB-IIIA Non-small Cell Lung Carcinoma	AstraZeneca	October 21 2015	Phase 3
NCT02529995	Completed	Drug: AZD9291 40 mg\|Drug: AZD9291 80 mg	Carcinoma Non-Small-Cell Lung With EGFR Mutation Positive	AstraZeneca	August 24 2015	Phase 1
NCT02491944	Completed	Drug: AZD9291\|Drug: [14C]AZD9291	Oncology	AstraZeneca	July 2015	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Can this formulation be used in mice? What are reconstitution instructions for in vivo with mice?
回答：
Osimertinib can be used for animal study. The vehicle we suggest is: 1% DMSO+30% PEG 300+dd H2O at up to 30mg/ml.

研究领域

产品类型

定制您的化合物库

Osimertinib (AZD9291)

客户使用Selleck生产的Osimertinib (AZD9291)发表文献213篇：

产品安全说明书

EGFR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Osimertinib (AZD9291) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

技术支持

常见问题及建议解决方法

EGFR Signaling Pathway Map

相关EGFR产品